Recent Research on Leukemia Has Revealed 85 Drug Candidates in Phase II or III Stage of Development and More Than 50 Companies Are Involved In the Development of These Drugs
Posted on: Thursday, 19 October 2006, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c43821) has announced the addition of Leukemia - A Therapeutic & Competitive Insight to their offering.
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry.
This has now clearly changed with the launch of Novartis' Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.
Research and analysis highlights
In the report "Leukemia - A Therapeutic & Competitive Insight" The author does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide a insight and framework to understand the complex field of leukemia therapeutics. In this report, the author provides one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. The author presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. The research has identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs. Among these drugs you can clearly see substantial progress while others have failed. There will be a more intense competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.
Scope of this report
Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current and future treatment strategies
Anticancer pipeline of most companies in the field
Key reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in leukemia R&D, and the results of clinical trials to date
Gain insight into the current challenges and commercial opportunities associated with leukemia therapy
More than 130 high quality references
Some of the drugs included in this analysis
AG-858, Alemtuzumab, AP23573, Atra, Avastin, BAY 43-9006, CEP-701, Ceplene, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, Imatinib, OSI-461, PKC412, PTK787, Rituximab, SU5416, Troxacitabine, Valspodar, VELCADE, Xcytrin and Zarnestra
Content Outline:
1 Executive Summary
2 Cancer Highlights
3 Methodology
4 Table of Contents
5 Introduction
6 Current Treatment Strategies
7 Progress in Current Treatment Strategies
8 Key Therapeutic Strategies for Future Therapies
9 Competitive Landscape in Drug Development: The Late Stage Pipeline
10 Current Drug Development: The Early Stage Pipeline
13 Drug Index
14 Company Index
4.1 List of Boxes
4.2 List of Tables
Some of the companies included in this analysis:
Amgen, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cephalon, Cyclacel Group (Cyclacel), Exelixis, Genta, GlaxoSmithKline, Johnson & Johnson, Millennium, Novartis, Pharmacyclics, PDL BioPharma, Schering-Plough, SuperGen, Vion Pharmaceuticals and Wyeth
For more information visit http://www.researchandmarkets.com/reports/c43821
Source: Business Wire
Related Articles
- Leading Drug Delivery Companies and TechnologiesCompe
- Alzheimer's Drug Discovery Foundation Funds PharmatrophiX to Develop Drugs to Prevent Neurodegenerative Disease
- Establishment of IOTA Pharmaceuticals, a New Fragment-Based Drug Discovery Company, With Research Centres in Cambridge (UK), Amsterdam (The Netherlands), and Ahmedabad (India)
- Gain An Insight Into The Pipeline Status Of Melanoma Or Skin Cancer Drugs By Company And By Stage As Well As A Summary Of The Latest News And Developments In This Area
- Gain an Insight into the Pipeline Status of Bacterial Infections Drugs By Company and By Stage As Well As a Summary of the Latest News and Developments in This Area
- Start-Up Gets $36 Million: TetraLogic, of Malvern, is Developing Drugs That Help the Body Kill a Variety of Cancer Cells
- World Mining Companies, Strategies for Growth
- Commentary: Techlink- Three MD-Based Firms Develop Drugs, Knowledge to Treat Problem of Obesity
- Companies to Develop Drug to Kill E.coli
 |
 |
User Comments (0)
RSS Feeds